Company Overview and News
Hitachi Ltd. will put profitability first in a nuclear plant construction project in the United Kingdom, President and CEO Toshiaki Higashihara told shareholders Wednesday.
SANTA CLARA, Calif., June 06, 2018 (GLOBE NEWSWIRE) -- Hitachi Vantara, a wholly owned subsidiary of Hitachi Ltd. (TSE:6501), today announced powerful hardware and software enhancements across the Hitachi Unified Compute Platform (UCP) family of converged, hyperconverged and rack-scale systems, including NVMe SSD caching and GPU processor-based server options. New certified applications ecosystem solutions optimized for mission-critical environments include SAP HANA®, Oracle databases, VMware and big data analytics frameworks.
LONDON (Reuters) - Britain is considering direct investment to help a unit of Japan’s Hitachi Ltd (6501.T) build a new nuclear power station in North Wales, the country’s business minister said on Monday.
LONDON – Britain is considering direct investment to help a unit of Japan’s Hitachi Ltd. build a new nuclear power station in North Wales, the country’s business minister said on Monday.
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
LONDON, June 4 (Reuters) - Britain is considering direct investment to help a unit of Japan’s Hitachi Ltd build a new nuclear power station in North Wales, the country’s business minister said on Monday.
LONDON, June 4 (Reuters) - British business minister Greg Clark said on Monday the government was considering direct investment to help a unit of Japan’s Hitachi Ltd to build nuclear reactors in North Wales.
SAGA, Japan — An increasing number of medical institutions are using smartphone apps to help improve the lifestyles of patients suffering from diabetes and heart failure while also providing them with better treatment.
(Reuters) - Private equity firm KKR & Co LP (KKR.N) wants to buy divisions from Japanese companies seeking to streamline their businesses in the world’s third-largest economy, co-Chief Executive Henry Kravis said on Friday.
Japan needs to raise its 8 percent consumption tax to 10 percent in October 2019 as planned, Hiroaki Nakanishi, new chairman of Keidanren (Japan Business Federation), said in a recent interview.
Traders said they expected the Bank of Japan to buy exchange-traded funds to support the market amid the morning weakness. - Reuters
7261 MZDAY TM SMFG TYT TOYOF SMFNF 532843 FORTIS 6501 8316 8306 MZDAF 7203 MUFG 8750 HTHIY MBFJF 8630 MTU
TOKYO, May 30 (Reuters) - Japan’s Nikkei share average tumbled to six-week lows on Wednesday morning after political turmoil in Italy sparked concerns about the stability of the euro zone, hurting most sectors on the board.
7261 MZDAY TM SMFG TYT TOYOF SMFNF 6501 8316 8306 MZDAF 7203 MUFG 8750 HTHIY MBFJF 8630 MTU
Apple Inc has decided to use OLED screens in all three new iPhone models planned for next year, according to South Korea's Electronic Times - a report that sent shares in Japan Display tumbling 10 percent.
6501 JNNDF AAPL 6740 JPDYY SNE SNEJF HTHIY
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
2018-06-11 - Asif
Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...
2018-06-11 - Asif
Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...